Evidence map›Paper›PMID 25672780›Full record

ArticleMolecular medicine reports2015

Protective effect of Flt3L on organ structure during advanced multiorgan dysfunction syndrome in mice.

Guang Tian, Jiangyang Lu, Huiqin Guo, Qian Liu, Hongwei Wang

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Guang TianDepartment of Pathology, The First Affiliated Hospital of General Hospital of PLA, Beijing 100048, P.R. China.
Jiangyang LuDepartment of Pathology, The First Affiliated Hospital of General Hospital of PLA, Beijing 100048, P.R. China.
Huiqin GuoDepartment of Thoracic Surgery, Peking Union Medical College Hospital, Beijing 100730, P.R. China.
Qian LiuDepartment of Pathology, The First Affiliated Hospital of General Hospital of PLA, Beijing 100048, P.R. China.
Hongwei WangDepartment of Pathology, The First Affiliated Hospital of General Hospital of PLA, Beijing 100048, P.R. China.
First Affiliated Hospital of Chinese PLA General Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study aimed to examine whether fms‑related tyrosine kinase 3 ligand (Flt3L) protects the organs of mice with multiorgan dysfunction syndrome (MODS). Male C57BL/6 mice were randomly assigned to normal control, MODS and Flt3L treatment groups. The mouse models of MODS were established using intraperitoneal zymosan injections, followed by normal saline injections. The treatment group received 5 µg/kg Flt3L for seven days, beginning on day five following zymosan injection. On day 12, the mortality rates of the Flt3L treatment and the MODS groups were 7 and 18%, respectively. Marked pathological changes were observed in the liver, lungs, kidneys and heart of the mice with MODS, including degeneration and focal necrosis of parenchyma cells. Mild pathological changes were observed in different organs of the Flt3L‑treated mice. In the MODS group, the number of CD4+ T lymphocytes was significantly reduced, whereas the number of CD8+ T lymphocytes was significantly increased compared with that in the normal control group; thus, the CD4+/CD8+ ratio was reduced. In the Flt3L treatment group, the average number of CD4+ T lymphocytes was not significantly different to the average number of CD4+ T lymphocytes in the normal group. In conclusion, Flt3L administration improved the immune status and alleviated the organ damage in mice with late‑phase MODS.

Indexed as

Adjuvants, ImmunologicAnimalsCD4-CD8 RatioCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesMaleMembrane ProteinsMice, Inbred C57BLMultiple Organ FailureZymosanAdjuvants, Immunologicflt3 ligand proteinMembrane ProteinsZymosan

Identifiers

PMID25672780
PMCPMC4408925
OpenAlexW2053908921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.